09 / INSIGHTS · COP · BIO
What the BIO keynotes and main sessions said —
and GRBM's answer
Five agendas from the June 2026 BIO International Convention in San Diego and the months since: the industrialization of AI, supply-chain realignment and biosecurity, the discipline of regulation and capital, purpose-driven innovation, and Korea's presence.
In plain words
BIO 2026 took place in San Diego from 22 to 25 June 2026 under the theme "Driven by Purpose", bringing together more than 20,000 biotech leaders in the year the industry marked its 50th anniversary.
Across keynotes, main sessions and on-site coverage, five words kept coming back: AI, supply chains and security, regulation and capital, purpose — and Korea. These five are likely to shape investors' questions all the way to BIO 2027 in Philadelphia.
Below we summarize each agenda briefly, together with the question investors will put to GRBM and our answer. The analysis is ELAN VITAL BIO's interpretation of public coverage and BIO announcements.
FIVE AGENDAS
Five agendas,
five answers
| Agenda | What BIO 2026 showed | The investor's question | GRBM's answer |
|---|---|---|---|
| Industrializing AI | The second annual AI Summit opened the convention, and AI ran as its own track | Does AI turn into real revenue and data assets? | AI Health Intelligence and the Metabolic Twin, accumulating metabolome fingerprints, human observations and intake data — products create data, and data creates the next products |
| Supply chains & biosecurity | BIO's chief executive framed biotech as a national-security imperative; U.S.–China supply-chain decoupling was a core theme | Are raw materials and processes tied to one country? | Metabolism by local plants and their own lactic acid bacteria alone — no dependence on chemical precursors, and raw materials can be grown in each country |
| Discipline of regulation & capital | Sessions on regulation and the FDA, and on investment and capital, outnumbered those on AI | How long will it burn cash before approval? | A dual path: enter the market first as food to generate revenue (GINSENG GRBM), and grow drug candidates (MHM-PI) through separate procedures |
| Purpose-driven innovation | "Driven by Purpose" — innovation that solves problems for patients and society | Which social problems does this technology solve? | 39 social problems in 9 fields — food, climate, chronic disease and ageing on one platform |
| Korea's presence | South Korea was the largest international delegation, and Korean organizations ran investor-matching events on site | What comes next for Korean biotech? | Not contract drug manufacturing but a Korean eco-bio platform — From Korea to the World |
AI reads the body;
GRBM changes it
Data becomes revenue only when there is a material that actually changes the body's metabolic environment, beyond measuring and predicting.
FOR 2027
What investors will check
at the 2027 events
- Does the platform expand into several industries at once, not one product? — 9-Way Platform
- Is there a flagship product that earns revenue now? — PANAX · GINSENG GRBM
- Are the technology rights clean? — 100% of the technology rights are held by the developer
- How is the evidence being built? — 600 people, 15 years of records and plans for disease-specific independent verification
- Does it connect with the climate and food agenda? — COP31 & GRBM
Read moreCloseSources and method
This analysis groups the agendas into five, based on BIO's official announcements, Bio.News and industry coverage. It summarizes the trends rather than quoting individual speakers.
- BIO International Convention Returns to San Diego (press release, 22 June 2026) — BIO
- BIO 2026: What to know about the AI Summit — Bio.News
- BIO on competing with China and modernizing the FDA — Bioprocess Online
- BIO 2026 recap, by the numbers — SynBioBeta
Analysis: ELAN VITAL BIO, 9 November 2026. Please check the sources for the content of each event.
PARTNERSHIP · INVESTMENT
The world's first true eco-bio platform technology —
we are looking for the one partner
After signing an NDA you can review the materials, then verify the original records and the process in person during on-site due diligence in Uljin, Gyeongsangbuk-do, Korea.